Week After Januvia Patent Is Upheld, Merck Sues Over Generic

By Adam Lidgett (October 4, 2022, 4:37 PM EDT) -- Merck has launched a suit claiming a New Jersey-based pharmaceutical company's proposed generic of the blockbuster diabetes drug Januvia infringes its patent on the treatment, less than a week after the Federal Circuit backed a Patent Trial and Appeal Board decision upholding the patent....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!